In the future, the circadian genes MBOAT2/CDA/LPCAT2/B4GALT5 may serve as prognostic and diagnostic biomarkers as well as drug targets for chronotherapy in PACA patients. Here, B4GALT5 is linked to permanent neonatal diabetes mellitus-pancreatic and cerebellar agenesis syndrome.